Gossamer Bio, Inc. (GOSS) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Gossamer Bio reported revenue of $48.5M, down 57.7% from $114.7M the year before. Net income was -$170.4M (a -351.5% net margin), or -$60.00 per diluted share. Operating margin was -352.2%. Operating activities generated -$171.3M of cash, leaving -$171.3M of free cash flow. At fiscal year end, Gossamer Bio held $172.2M in total assets against $295.0M in total liabilities, including $37.7M of cash and equivalents.
Open the full interactive Gossamer Bio financials → Quarterly statements, key ratios, valuation history and price charts.
Gossamer Bio Key Stats
| Share Price | $9.76 |
|---|---|
| Market Cap | $40.1M |
| Revenue YoY Growth | -57.7% |
| 52-Week Range | $9.28 – $303.20 |
| Shares Outstanding | 4.0 million (basic, 2026 Q2) |
Gossamer Bio Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $114.7M | $48.5M |
| Operating Income | -$234.0M | -$216.1M | -$218.6M | -$183.8M | -$59.9M | -$170.7M |
| Pre-Tax Income | -$243.4M | -$234.0M | -$229.4M | -$179.8M | -$55.6M | -$170.5M |
| Income Tax | — | $8,000 | $8,000 | $8,000 | $893,000 | -$88,000 |
| Net Income | -$243.4M | -$234.0M | -$229.4M | -$179.8M | -$56.5M | -$170.4M |
| Diluted EPS | -$284.00 | -$250.40 | -$216.80 | -$94.40 | -$20.00 | -$60.00 |
Gossamer Bio Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $13.3M | $13.8M | $17.0M | $9.2M |
| Net Income | -$48.2M | -$47.2M | -$46.7M | $16.9M |
| Diluted EPS | -$16.80 | -$0.21 | -$16.00 | -$6.40 |
Gossamer Bio Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $486.1M | $183.4M | $112.0M | $32.1M | $46.1M | $37.7M |
| Current Assets | $522.3M | $331.8M | $261.9M | $306.5M | $309.9M | $167.6M |
| Total Assets | $539.4M | $343.7M | $272.4M | $311.9M | $315.3M | $172.2M |
| Current Liabilities | $38.6M | $39.9M | $49.2M | $51.6M | $45.0M | $63.4M |
| Total Long-Term Debt | $28.7M | $29.1M | $23.6M | $12.4M | — | — |
| Total Liabilities | $218.7M | $222.2M | $260.4M | $249.1M | $285.8M | $295.0M |
| Shareholders' Equity | $320.7M | $121.5M | $12.1M | $62.8M | $29.5M | -$122.8M |
Gossamer Bio Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$176.4M | -$188.9M | -$187.0M | -$159.2M | -$3.5M | -$171.3M |
| Cash From Investing | $215.3M | -$117.4M | -$1.0M | -$111.0M | $29.0M | $156.4M |
| Cash From Financing | $312.5M | $3.3M | $117.1M | $190.2M | -$11.5M | $6.4M |
| Free Cash Flow | -$177.9M | -$190.4M | -$187.4M | -$159.2M | -$3.5M | -$171.3M |
Figures from Gossamer Bio's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Gossamer Bio financials page for every line item.
Gossamer Bio Company Profile
| Ticker | GOSS |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001728117 |
Frequently Asked Questions
What was Gossamer Bio's revenue in fiscal 2025?
Gossamer Bio (GOSS) reported revenue of $48.5M for fiscal 2025.
What is Gossamer Bio's annual revenue history?
Gossamer Bio's annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $114.7M; 2025: $48.5M.
What was Gossamer Bio's net income in fiscal 2025?
Gossamer Bio reported net income of -$170.4M for fiscal 2025.
What was Gossamer Bio's earnings per share (EPS) in fiscal 2025?
Gossamer Bio's diluted EPS was -$60.00 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Gossamer Bio generate in fiscal 2025?
Gossamer Bio generated -$171.3M of free cash flow in fiscal 2025.
What was Gossamer Bio's revenue last quarter?
In its most recent reported quarter (2026 Q2), Gossamer Bio reported revenue of $9.2M.
How many shares of Gossamer Bio are outstanding?
Gossamer Bio reported a weighted average of 4.0 million basic shares outstanding in 2026 Q2.
What is Gossamer Bio's market cap?
Based on its latest closing price, Gossamer Bio (GOSS) has a market capitalization of about $40.1M.
When does Gossamer Bio's fiscal year end?
Gossamer Bio's fiscal year end, as registered with the SEC, is December 31.
Where is Gossamer Bio headquartered?
Gossamer Bio lists its business address in San Diego, California in its SEC filings.